Combined metabolic activators improve cognitive functions in Alzheimer's disease patients: a randomised, double-blinded, placebo-controlled phase-II trial
Özet
Background Alzheimer's disease (AD) is associated with metabolic abnormalities linked to critical elements of neurodegeneration. We recently administered combined metabolic activators (CMA) to the AD rat model and observed that CMA improves the AD-associated histological parameters in the animals. CMA promotes mitochondrial fatty acid uptake from the cytosol, facilitates fatty acid oxidation in the mitochondria, and alleviates oxidative stress.Methods Here, we designed a randomised, double-blinded, placebo-controlled phase-II clinical trial and studied the effect of CMA administration on the global metabolism of AD patients. One-dose CMA included 12.35 g L-serine (61.75%), 1 g nicotinamide riboside (5%), 2.55 g N-acetyl-L-cysteine (12.75%), and 3.73 g L-carnitine tartrate (18.65%). AD patients received one dose of CMA or placebo daily during the first 28 days and twice daily between day 28 and day 84. The primary endpoint was the difference in the cognitive function and daily living activity scores between the placebo and the treatment arms. The secondary aim of this study was to evaluate the safety and tolerability of CMA. A comprehensive plasma metabolome and proteome analysis was also performed to evaluate the efficacy of the CMA in AD patients.Results We showed a significant decrease of AD Assessment Scale-cognitive subscale (ADAS-Cog) score on day 84 vs day 0 (P = 0.00001, 29% improvement) in the CMA group. Moreover, there was a significant decline (P = 0.0073) in ADAS-Cog scores (improvement of cognitive functions) in the CMA compared to the placebo group in patients with higher ADAS-Cog scores. Improved cognitive functions in AD patients were supported by the relevant alterations in the hippocampal volumes and cortical thickness based on imaging analysis. Moreover, the plasma levels of proteins and metabolites associated with NAD + and glutathione metabolism were significantly improved after CMA treatment.Conclusion Our results indicate that treatment of AD patients with CMA can lead to enhanced cognitive functions and improved clinical parameters associated with phenomics, metabolomics, proteomics and imaging analysis.
Anahtar kelimeler
Atıf için künye
Yulug, B., Altay, O., Li, X., Hanoglu, L., Cankaya, S., Lam, S., Velioglu, H. A., Yang, H., Coskun, E., Idil, E., Nogaylar, R., Ozsimsek, A., Bayram, C., Bolat, İ., Oner, S., Tozlu, O. O., Arslan, M. E., Hacımüftüoğlu, A., Yıldırım, S., … Mardinoglu, A. (2023). Combined metabolic activators improve cognitive functions in Alzheimer's disease patients: a randomised, double-blinded, placebo-controlled phase-II trial. TRANSLATIONAL NEURODEGENERATION, 12(1). https://doi.org/10.1186/s40035-023-00336-2
BibTeX
@article{yulug2023-232272,
author = {Yulug, Burak and Altay, Ozlem and Li, Xiangyu and Hanoglu, Lutfu and Cankaya, Seyda and Lam, Simon and Velioglu, Halil Aziz and Yang, Hong and Coskun, Ebru and Idil, Ezgi and Nogaylar, Rahim and Ozsimsek, Ahmet and Bayram, Cemil and Bolat, İsmail and Oner, Sena and Tozlu, Ozlem Ozdemir and Arslan, Mehmet Enes and Hacımüftüoğlu, Ahmet and Yıldırım, Serkan and Arif, Muhammad and Shoaie, Saeed and Zhang, Cheng and Nielsen, Jens and Türkez, Hasan and Borén, Jan and Uhlén, Mathias and Mardinoglu, Adil},
title = {Combined metabolic activators improve cognitive functions in Alzheimer's disease patients: a randomised, double-blinded, placebo-controlled phase-II trial},
journal = {TRANSLATIONAL NEURODEGENERATION},
year = {2023},
volume = {12},
number = {1},
issn = {2047-9158},
doi = {10.1186/s40035-023-00336-2},
url = {https://akademik.atauni.edu.tr/yayinlar/232272-combined-metabolic-activators-improve-cognitive-functions-in-alzheimers-disease}
}